Read More

Gilead Strengthens Early Pipeline In Oncology And Inflammation Through The Acquisition Of XinThera; Financial Terms Of Transaction Not Disclosed; Expect Deal To Reduce Gilead’s GAAP And Non-GAAP 2023 EPS By ~$0.12-$0.15

– Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the acquisition of all outstanding shares of

GILD

Read More

‘Private-Equity Giant Apollo Is Part Of A Bid To Buy Bankrupt Crypto Firm Celsius; The $500B+ Firm Is Involved In Novawulf’s Offer For Celsius, According To A Person Familiar With The Matter’ – CoinDesk

https://www.coindesk.com/business/2023/05/08/private-equity-giant-apollo-is-part-of-a-bid-to-buy-bankrupt-crypto-firm-celsius/?utm_term=organic&utm_source=twitter&utm_medium=social&utm_content=editorial&utm_campaign=coindesk_main

APO